Related Experiment Video
Updated: Dec 10, 2025
09:44
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
512
Repurposing GLP1 agonists for neurodegenerative diseases.
Ioanna Markaki1, Kristian Winther2, Sergiu-Bogdan Catrina3
1Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center of Neurology, Academic Specialist Center, Stockholm, Sweden.
International Review of Neurobiology
|August 29, 2020
Summary
Strategies targeting insulin sensitivity in the brain show promise for treating neurodegenerative diseases like Parkinson's and Alzheimer's. Glucagon-like peptide 1 (GLP1) agonism offers potential neuroprotection, guiding future drug development.
Area of Science:
- Neuroscience
- Endocrinology
- Pharmacology
Background:
- Neurodegenerative diseases lack effective disease-modifying therapies.
- Insulin resistance is increasingly recognized as a factor in neurodegeneration.
- Restoring neuronal insulin sensitivity may offer neuroprotective benefits.
Purpose of the Study:
- To review evidence linking insulin resistance to neurodegeneration.
- To explore therapeutic strategies for normalizing insulin sensitivity in neurons.
- To discuss the neuroprotective potential of glucagon-like peptide 1 (GLP1) agonism and dipeptidyl peptidase-4 inhibition.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of mechanistic insights into insulin signaling in neurodegeneration.
- Examination of drug development strategies targeting GLP1 pathways.
Main Results:
- Insulin resistance is prevalent in neurodegenerative conditions.
- GLP1 agonism and dipeptidyl peptidase-4 inhibition demonstrate neuroprotective effects in Parkinson's and Alzheimer's disease models.
- These findings highlight the therapeutic potential of targeting insulin pathways.
Conclusions:
- Normalizing insulin sensitivity in neurons is a viable therapeutic strategy for neurodegenerative diseases.
- GLP1 agonism presents a promising avenue for developing novel neuroprotective drugs.
- Further research into GLP1-based therapies could address the unmet need for disease-modifying treatments.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
677
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
677
01:15Parkinson's Disease: Overview
1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
01:24Parkinson's Disease: Treatment
815
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
815
01:06Oral Hypoglycemic Agents: Glinides
472
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
472
01:15G Protein-coupled Receptors
15.6K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
15.6K
01:23Dipeptidyl Peptidase 4 Inhibitors
434
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
434